BDX - Becton Dickinson: Low Volatility Is A Strength In The Current Market

• We expect the interventional segment to continue maintaining its high growth as Becton, Dickinson focuses on transformational solutions.
• We believe the company may receive FDA clearance for its Alaris systems by April 2022, based on the average time for regulatory clearance in Europe and Canada along with a year.
• Our analysis shows diabetes spin-off positively impacting the medical segment average revenue growth by 0.24% from 2024 onwards.
• The company's low volatility (beta) results in a high valuation of its shares, especially in the current volatile market.

For further details see: